EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On May 4, 2017, EyeGate Pharmaceuticals, Inc. (the Company)
issued a press release announcing that it has submitted an
Investigational Device Exemption, or IDE, for its EyeGate Ocular
Bandage Gel (EyeGate OBG) product with the U.S. Food and Drug
Administration.
The press release is furnished as Exhibit 99.1 and investors
should read the press release in its entirety, including the
cautionary statement regarding forward looking statements
therein.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The Company hereby furnishes the following exhibit:
| 99.1 | Press Release of the Company, dated as of May 4, 2017. |
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye. EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Recent Trading Information
EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) closed its last trading session up +0.01 at 1.93 with 11,788 shares trading hands.